Evidence map›Paper›PMID 27195491›Full record

ArticlePLoS genetics2016

A Syntenic Cross Species Aneuploidy Genetic Screen Links RCAN1 Expression to β-Cell Mitochondrial Dysfunction in Type 2 Diabetes.

Heshan Peiris, Michael D Duffield, Joao Fadista, Claire F Jessup, Vinder Kashmir, Amanda J Genders, Sean L McGee, Alyce M Martin, Madiha Saiedi, Nicholas Morton and 22 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 98 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 15 institutions in 5 countries.

Heshan PeirisDepartment of Human Physiology and Centre for Neuroscience, Flinders University, Adelaide, South Australia, Australia.
Michael D DuffieldDepartment of Human Physiology and Centre for Neuroscience, Flinders University, Adelaide, South Australia, Australia.
Joao FadistaLund University Diabetes Centre, Malmö, Sweden.
Claire F JessupIslet Biology Laboratory, Department of Anatomy and Histology and Centre for Neuroscience, Flinders University, Adelaide, South Australia, Australia.ORCID 0000-0003-1184-6653
Vinder KashmirDepartment of Human Physiology and Centre for Neuroscience, Flinders University, Adelaide, South Australia, Australia.
Amanda J GendersMetabolic Remodelling Laboratory, Metabolic Research Unit, School of Medicine, Deakin University, Geelong, Australia.
Sean L McGeeMetabolic Remodelling Laboratory, Metabolic Research Unit, School of Medicine, Deakin University, Geelong, Australia.
Alyce M MartinDepartment of Human Physiology and Centre for Neuroscience, Flinders University, Adelaide, South Australia, Australia.
Madiha SaiediDepartment of Human Physiology and Centre for Neuroscience, Flinders University, Adelaide, South Australia, Australia.
Nicholas MortonQueen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.
Roderick CarterQueen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.
Michael A CousinCentre for Integrative Physiology, University of Edinburgh, Edinburgh, United Kingdom.
Alexandros C KokotosCentre for Integrative Physiology, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0003-4024-9866
Nikolay OskolkovLund University Diabetes Centre, Malmö, Sweden.
Petr VolkovLund University Diabetes Centre, Malmö, Sweden.
Tertius A HoughMary Lyon Centre Pathology, MRC Harwell, Harwell Oxford Science Park, Oxford, United Kingdom.
Elizabeth M C FisherDepartment of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.
Victor L J TybulewiczFrancis Crick Institute, Mill Hill, London, United Kingdom.
Jorge BusciglioDepartment of Neurobiology and Behaviour, University of California, Irvine, Irvine, California, United States of America.
Pinar E CoskunDepartment of Neurobiology and Behaviour, University of California, Irvine, Irvine, California, United States of America.
Ann BeckerDepartment of Neurosciences School of Medicine, University of California, San Diego, San Diego, California, United States of America.
Pavel V BelichenkoDepartment of Neurosciences School of Medicine, University of California, San Diego, San Diego, California, United States of America.
William C MobleyDepartment of Neurosciences School of Medicine, University of California, San Diego, San Diego, California, United States of America.
Michael T RyanDepartment of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia.
Jeng Yie ChanDiabetes and Metabolism Division, Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
D Ross LaybuttDiabetes and Metabolism Division, Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
P Toby CoatesClinical and Experimental Transplantation Group, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia.
Sijun YangAnimal Experiment Center, Animal Biosafety Level-III Laboratory, Wuhan University, Wuhan, China.
Charlotte LingLund University Diabetes Centre, Malmö, Sweden.
Leif GroopLund University Diabetes Centre, Malmö, Sweden.
Melanie A PritchardDepartment of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia.
Damien J KeatingDepartment of Human Physiology and Centre for Neuroscience, Flinders University, Adelaide, South Australia, Australia.
Flinders University · AULund University · SEUniversity of California San Diego · USGarvan Institute of Medical Research · AUMonash University · AUThe Queen's Medical Research Institute · GBUniversity of California, Irvine · USUniversity of Edinburgh · GBBaker Heart and Diabetes Institute · AUDeakin University · AUMary Lyon Centre at MRC Harwell · GBRoyal Adelaide Hospital · AUThe Francis Crick Institute · GBUniversity College London · GBWuhan University · CN

Funding

Cancer Research UKMedical Research Council G0601056Medical Research Council MC_UP_1502/1Wellcome TrustWellcome Trust 080174Wellcome Trust 098328
6 · The paper itself

Abstract

Type 2 diabetes (T2D) is a complex metabolic disease associated with obesity, insulin resistance and hypoinsulinemia due to pancreatic β-cell dysfunction. Reduced mitochondrial function is thought to be central to β-cell dysfunction. Mitochondrial dysfunction and reduced insulin secretion are also observed in β-cells of humans with the most common human genetic disorder, Down syndrome (DS, Trisomy 21). To identify regions of chromosome 21 that may be associated with perturbed glucose homeostasis we profiled the glycaemic status of different DS mouse models. The Ts65Dn and Dp16 DS mouse lines were hyperglycemic, while Tc1 and Ts1Rhr mice were not, providing us with a region of chromosome 21 containing genes that cause hyperglycemia. We then examined whether any of these genes were upregulated in a set of ~5,000 gene expression changes we had identified in a large gene expression analysis of human T2D β-cells. This approach produced a single gene, RCAN1, as a candidate gene linking hyperglycemia and functional changes in T2D β-cells. Further investigations demonstrated that RCAN1 methylation is reduced in human T2D islets at multiple sites, correlating with increased expression. RCAN1 protein expression was also increased in db/db mouse islets and in human and mouse islets exposed to high glucose. Mice overexpressing RCAN1 had reduced in vivo glucose-stimulated insulin secretion and their β-cells displayed mitochondrial dysfunction including hyperpolarised membrane potential, reduced oxidative phosphorylation and low ATP production. This lack of β-cell ATP had functional consequences by negatively affecting both glucose-stimulated membrane depolarisation and ATP-dependent insulin granule exocytosis. Thus, from amongst the myriad of gene expression changes occurring in T2D β-cells where we had little knowledge of which changes cause β-cell dysfunction, we applied a trisomy 21 screening approach which linked RCAN1 to β-cell mitochondrial dysfunction in T2D.

Indexed as

Adenosine TriphosphateAneuploidyAnimalsCalcium-Binding ProteinsChromosomes, Human, Pair 21Diabetes Mellitus, Type 2Down SyndromeGene Expression RegulationGlucoseHumansHyperglycemiaInsulinInsulin-Secreting CellsIntracellular Signaling Peptides and ProteinsMiceMitochondriaAdenosine TriphosphateCalcium-Binding ProteinsDSCR1 protein, mouseGlucoseInsulinIntracellular Signaling Peptides and ProteinsMuscle Proteins

Identifiers

PMID27195491
PMCPMC4873152
OpenAlexW2399665638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.